The greedy, price-hiking ways of Turing, Mylan, Valent, and countless others are breaking out like blemishes across the face of the pharmaceutical industry. So it may come as no surprise that a simple acne cream, called Aloquin, saw its price hit a whopping $9,561 (£7,400) last week.

The 60g tube of zit-zapping topical previously cost just $241.50—but that was months ago, before Chicago-based Novum Pharma bought the medication from Primus Pharmaceuticals in May of 2015 and made no changes to the product at all. Since then, Novum hiked the price three times, reaching an increase of 3,900 percent.

Like many other drugs that have seen huge and sudden price hikes, Aloquin is old and cheap to make. It consists of two main ingredients: iodoquinol, a generic, longstanding antibiotic; and extracts from the aloe vera plant. As the Financial Times points out, a similar cream containing the iodoquinol costs less than $30, and aloe vera extracts are just a few dollars.

However, Aloquin has one striking difference from other drugs that have seen rage-inducing price hikes. Namely, Aloquin, used to treat acne and eczema, isn’t a life-saving or even all that effective drug. The Food and Drug Administration has dubbed it “possibly effective,” meaning there’s scant clinical data indicating it’s safe and it works. That’s a stark contrast from Mylan’s EpiPens, which effectively rein in deadly allergic reactions, and Turing’s Daraprim, which cures a parasitic infection and is often given to babies and patients with HIV/AIDS. Those drugs saw their prices increase by more than 500 percent and 5,000 percent, respectively.

Still, Novum's price hikes stand to pinch customers who may rely on the cream. (It has also raised the prices of other products its acquired.) The drug maker, like the others, offers coupons to spare customers from heavy out-of-pocket costs. However, the remaining costs often get passed on to insurance companies, which in turn contributes to rising premiums paid by customers.

If only there was a cream for this.